Protein / target
Bcl-2-like protein 1
Protein at a glance
Biological role
Identical protein binding
Primary system
Immune system
Strongest disease association
neurodegenerative disease
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
1 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis
Subcellular location
Domains and Gene Ontology detail (38)Hide
Gene Ontology
- CBcl-2 family protein complex
- Ccentrosome
- Ccytoplasm
- Ccytosol
- Cendoplasmic reticulum
- Cmitochondrial inner membrane
- Cmitochondrial matrix
- Cmitochondrial outer membrane
- Cmitochondrion
- Cnuclear membrane
- Csynaptic vesicle membrane
- FBH3 domain binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cel…
- ·regulation of cytokinesis
- ·response to cytokine
- ·Interleukin-4 and Interleukin-13 signaling
Apoptosis & cell death
- ·Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cel…
- ·negative regulation of apoptotic process
- ·positive regulation of apoptotic process
- ·SARS-CoV-1-mediated effects on programmed cell death
Kinase signalling
- ·protein kinase binding
View underlying pathways (7)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Apoptosis regulator Bcl-X inhibitor
Appears in clinical studies involving neoplasm, myelofibrosis, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 972 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 3 total
follicular lymphoma · acute myeloid leukemia · small cell lung carcinoma
neoplasm · myelofibrosis · B-cell chronic lymphocytic leukemia
small cell lung carcinoma · Hodgkins lymphoma · myelofibrosis
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (18)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.